Posts by: Patricia Inacio

News

A protein called cadherin-11 (CDH11) ties together macrophages and myofibroblasts in an “eternal hug” in the lungs of idiopathic pulmonary fibrosis (IPF) patients, promoting a profibrotic environment, a study ... Read more

January 23, 2019January 31, 2019

Real-world Use of Esbriet and Ofev Supports Their Safety and Tolerability, Study Says

Esbriet, News

The tolerability and safety of Ofev (nintedanib) and Esbriet (pirfenidone) treatments in a small group of patients with idiopathic pulmonary fibrosis (IPF) in South England were found to be ... Read more

January 11, 2019January 15, 2019

Sprycel/Quercetin Combo Therapy Improves Physical Function in IPF Patients, Phase 1 Trial Shows

News

A Phase 1 trial shows that combining Sprycel (dasatinib) with the plant-based flavonoid quercetin improved the physical function of people with idiopathic pulmonary fibrosis (IPF). However, patients’ pulmonary function ... Read more

December 17, 2018December 17, 2018

Potential Role of Ninj1 Protein in Promoting Pulmonary Fibrosis Uncovered in Study

News

The nerve injury-induced protein 1 (Ninjurin1, or Ninj1) may contribute to pulmonary fibrosis (PF) by promoting the inflammatory response of immune cells, called macrophages, leading to the activation of lung fibroblasts, a ... Read more

December 7, 2018December 11, 2018

Esbriet Extends IPF Patient Survival, Real-world Study Reports

Esbriet, News

Esbriet (pirfenidone) can improve survival rates of idiopathic pulmonary fibrosis (IPF) patients by 30 percent, a real-world retrospective analysis shows. The study, “Pirfenidone improves survival in IPF: results from a ... Read more

November 27, 2018November 27, 2018

Pre-existing PF Increases Risk of Lung Inflammation Among Lung Cancer Patients Using Opdivo or Keytruda, Study Suggests

News

Pulmonary fibrosis significantly increases the risk of severe pneumonitis (inflammation of lung tissue) among patients with lung cancer who were treated with Opdivo or Keytruda, a retrospective study suggests. The study “Pre-existing ... Read more

November 14, 2018November 20, 2018

Ofev Maintains Effectiveness in Advanced IPF Patients, Real-world Study Shows

News

Ofev (nintedanib) shows a similar ability to reduce lung function decline in patients with advanced idiopathic pulmonary fibrosis (IPF) as those with milder disease, according to a real-world clinical study. ... Read more

November 7, 2018November 13, 2018

BML-111 Found to Suppress Lung Fibrosis in Mouse Model by Inhibiting Signaling Molecules

News

BML‐111, a potent activator of the natural anti-inflammatory lipoxin A4 receptor, protects lungs from fibrosis by inhibiting fibroblast activation and decreasing the levels of inflammatory signaling molecules, a mouse ... Read more

October 15, 2018November 19, 2018

Pharmaxis’ LOXL2 Inhibitor Shows Positive Results in Phase 1 Trial in Healthy Volunteers

News

Pharmaxis’ first small molecule inhibitor of LOXL2 (lysyl oxidase like 2), an enzyme that promotes fibrosis in the lungs of idiopathic pulmonary fibrosis (IPF) patients, was found safe and well-tolerated ... Read more

September 28, 2018October 2, 2018

Esbriet and Ofev Show Significant Benefits in Real-Life Clinical Setting

Esbriet, News

Treatment with Esbriet (pirfenidone) or Ofev (nintedanib) significantly slowed the progression of idiopathic pulmonary fibrosis (IPF) in a real-life clinical setting, an Italian study reported. The study, “Pirfenidone and Nintedanib ... Read more

Posts by: Patricia Inacio

Patricia Inacio

Specific Protein Promotes Cell Interaction that Fuels Profibrotic Environment, Study Finds

Real-world Use of Esbriet and Ofev Supports Their Safety and Tolerability, Study Says

Sprycel/Quercetin Combo Therapy Improves Physical Function in IPF Patients, Phase 1 Trial Shows

Potential Role of Ninj1 Protein in Promoting Pulmonary Fibrosis Uncovered in Study

Esbriet Extends IPF Patient Survival, Real-world Study Reports

Pre-existing PF Increases Risk of Lung Inflammation Among Lung Cancer Patients Using Opdivo or Keytruda, Study Suggests

Ofev Maintains Effectiveness in Advanced IPF Patients, Real-world Study Shows

BML-111 Found to Suppress Lung Fibrosis in Mouse Model by Inhibiting Signaling Molecules

Pharmaxis’ LOXL2 Inhibitor Shows Positive Results in Phase 1 Trial in Healthy Volunteers

Esbriet and Ofev Show Significant Benefits in Real-Life Clinical Setting

Pin It on Pinterest